Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review
ConclusionRAM + PTX as a second-line treatment is effective and associated with an acceptable toxicity profile in patients with advanced or metastatic G/GEA in real-world settings of Japan and South Korea. More studies are recommended to further evaluate effectiveness and safety of RAM or RAM-based therapy, especially after anti-PD-1 therapy, in a wider Eastern Asian population.Trial RegistrationINPLASY registration number INPLASY2022120023.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Abraxane | Adenocarcinoma | Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Drugs & Pharmacology | Gastric (Stomach) Cancer | Gastroenterology | Hematology | Japan Health | South Korea Health | Study | Toxicology